Literature DB >> 22527793

Opioid system and Alzheimer's disease.

Zhiyou Cai1, Anna Ratka.   

Abstract

The opioid system may be involved in the pathogenesis of AD, including cognitive impairment, hyperphosphorylated tau, Aβ production, and neuroinflammation. Opioid receptors influence the regulation of neurotransmitters such as acetylcholine, norepinephrine, GABA, glutamate, and serotonin which have been implicated in the pathogenesis of AD. Opioid system has a close relation with Aβ generation since dysfunction of opioid receptors retards the endocytosis and degradation of BACE1 and γ-secretase and upregulates BACE1 and γ-secretase, and subsequently, the production of Aβ. Conversely, activation of opioid receptors increases the endocytosis of BACE1 and γ-secretase and downregulates BACE1 and γ-secretase, limiting the production of Aβ. The dysfunction of opioid system (opioid receptors and opioid peptides) may contribute to hyperphosphorylation of tau and neuroinflammation, and accounts for the degeneration of cholinergic neurons and cognitive impairment. Thus, the opioid system is potentially related to AD pathology and may be a very attractive drug target for novel pharmacotherapies of AD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22527793     DOI: 10.1007/s12017-012-8180-3

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  322 in total

1.  Mu-, delta- and kappa-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients.

Authors:  A M Mathieu-Kia; L Q Fan; M J Kreek; E J Simon; J M Hiller
Journal:  Brain Res       Date:  2001-03-02       Impact factor: 3.252

Review 2.  Neurotransmitter receptors in the central nervous system and aging: pharmacological aspect (review).

Authors:  S G Burchinsky
Journal:  Exp Gerontol       Date:  1984       Impact factor: 4.032

Review 3.  Opiate receptors and opioid peptides.

Authors:  S H Snyder; S R Childers
Journal:  Annu Rev Neurosci       Date:  1979       Impact factor: 12.449

4.  Opioid peptide receptor studies. 16. Chronic morphine alters G-protein function in cells expressing the cloned mu opioid receptor.

Authors:  Heng Xu; Yi-Feng Lu; Richard B Rothman
Journal:  Synapse       Date:  2003-01       Impact factor: 2.562

5.  Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective.

Authors:  Filippo Caraci; Gemma Molinaro; Giuseppe Battaglia; Maria Laura Giuffrida; Barbara Riozzi; Anna Traficante; Valeria Bruno; Milena Cannella; Sara Merlo; Xushan Wang; Beverly A Heinz; Eric S Nisenbaum; Thomas C Britton; Filippo Drago; Maria Angela Sortino; Agata Copani; Ferdinando Nicoletti
Journal:  Mol Pharmacol       Date:  2010-12-15       Impact factor: 4.436

Review 6.  Nicotine and endogenous opioids: neurochemical and pharmacological evidence.

Authors:  Maria Hadjiconstantinou; Norton H Neff
Journal:  Neuropharmacology       Date:  2010-11-22       Impact factor: 5.250

Review 7.  The biology of the opioid growth factor receptor (OGFr).

Authors:  Ian S Zagon; Michael F Verderame; Patricia J McLaughlin
Journal:  Brain Res Brain Res Rev       Date:  2002-02

8.  Beta-endorphin, somatostatin, and prolactin levels in cerebrospinal fluid of epileptic patients after generalised convulsion.

Authors:  A Pitkänen; J Jolkkonen; P Riekkinen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-10       Impact factor: 10.154

Review 9.  Neurotransmitters in the cerebral cortex.

Authors:  E G Jones
Journal:  J Neurosurg       Date:  1986-08       Impact factor: 5.115

10.  Complete knockout of the nociceptin/orphanin FQ receptor in the rat does not induce compensatory changes in mu, delta and kappa opioid receptors.

Authors:  J R Homberg; J D Mul; E de Wit; E Cuppen
Journal:  Neuroscience       Date:  2009-06-12       Impact factor: 3.590

View more
  17 in total

Review 1.  [Status and perspectives of pain and pain therapy in old age : Plea for better care of geriatric pain patients].

Authors:  Corinna Drebenstedt; Matthias Schuler
Journal:  Z Gerontol Geriatr       Date:  2017-09-21       Impact factor: 1.281

2.  Development and In Vivo Evaluation of a κ-Opioid Receptor Agonist as a PET Radiotracer with Superior Imaging Characteristics.

Authors:  Songye Li; Ming-Qiang Zheng; Mika Naganawa; Sujin Kim; Hong Gao; Michael Kapinos; David Labaree; Yiyun Huang
Journal:  J Nucl Med       Date:  2019-01-10       Impact factor: 10.057

3.  Pimavanserin, a 5HT2A receptor inverse agonist, rapidly suppresses Aβ production and related pathology in a mouse model of Alzheimer's disease.

Authors:  Carla M Yuede; Clare E Wallace; Todd A Davis; Woodrow D Gardiner; Jane C Hettinger; Hannah M Edwards; Rachel D Hendrix; Brookelyn M Doherty; Kayla M Yuede; Ethan S Burstein; John R Cirrito
Journal:  J Neurochem       Date:  2021-01-10       Impact factor: 5.372

4.  Experimentally evoked pain in Alzheimer's disease.

Authors:  Alison R Anderson; W Larkin Iversen; Michael A Carter; Karen O Moss; Ronald L Cowan; Todd B Monroe
Journal:  J Am Assoc Nurse Pract       Date:  2021-03-12       Impact factor: 1.495

Review 5.  Positive Social Interactions in a Lifespan Perspective with a Focus on Opioidergic and Oxytocinergic Systems: Implications for Neuroprotection.

Authors:  Valentina Colonnello; Nicola Petrocchi; Marina Farinelli; Cristina Ottaviani
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

6.  Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.

Authors:  Angel Agis-Torres; Monica Sölhuber; Maria Fernandez; J M Sanchez-Montero
Journal:  Curr Neuropharmacol       Date:  2014-01       Impact factor: 7.363

7.  AlzPlatform: an Alzheimer's disease domain-specific chemogenomics knowledgebase for polypharmacology and target identification research.

Authors:  Haibin Liu; Lirong Wang; Mingliang Lv; Rongrong Pei; Peibo Li; Zhong Pei; Yonggang Wang; Weiwei Su; Xiang-Qun Xie
Journal:  J Chem Inf Model       Date:  2014-03-20       Impact factor: 4.956

Review 8.  G Protein-Coupled Receptors (GPCRs) in Alzheimer's Disease: A Focus on BACE1 Related GPCRs.

Authors:  Juan Zhao; Yulin Deng; Zhaotan Jiang; Hong Qing
Journal:  Front Aging Neurosci       Date:  2016-03-24       Impact factor: 5.750

9.  A Rat Model of Alzheimer's Disease Based on Abeta42 and Pro-oxidative Substances Exhibits Cognitive Deficit and Alterations in Glutamatergic and Cholinergic Neurotransmitter Systems.

Authors:  Tomas Petrasek; Martina Skurlova; Kristyna Maleninska; Iveta Vojtechova; Zdena Kristofikova; Hana Matuskova; Jana Sirova; Karel Vales; Daniela Ripova; Ales Stuchlik
Journal:  Front Aging Neurosci       Date:  2016-04-20       Impact factor: 5.750

Review 10.  Role of berberine in Alzheimer's disease.

Authors:  Zhiyou Cai; Chuanling Wang; Wenming Yang
Journal:  Neuropsychiatr Dis Treat       Date:  2016-10-03       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.